DK1954718T3 - Anti-A-globulomer-antistoffer, antigenbindingsgrupper deraf, tilsvarende hybridomer, nucleinsyrer, vektorer, værtsceller, fremgangsmåder til fremstilling af nævnte antistoffer, - Google Patents

Anti-A-globulomer-antistoffer, antigenbindingsgrupper deraf, tilsvarende hybridomer, nucleinsyrer, vektorer, værtsceller, fremgangsmåder til fremstilling af nævnte antistoffer, Download PDF

Info

Publication number
DK1954718T3
DK1954718T3 DK06818937.2T DK06818937T DK1954718T3 DK 1954718 T3 DK1954718 T3 DK 1954718T3 DK 06818937 T DK06818937 T DK 06818937T DK 1954718 T3 DK1954718 T3 DK 1954718T3
Authority
DK
Denmark
Prior art keywords
antibody
seq
amino acid
obtainable
globulomer
Prior art date
Application number
DK06818937.2T
Other languages
English (en)
Inventor
Stefan Barghorn
Ulrich Ebert
Heinz Hillen
Patrick Keller
Andreas Striebinger
Boris Labkovsky
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Application granted granted Critical
Publication of DK1954718T3 publication Critical patent/DK1954718T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Claims (35)

1. Monoklonalt antistof med en bindingsaffinitet til en Αβ(20-42) globulomer, som er mindst 10 gange større end bindingsaffiniteten af antistoffet til en Αβ(1-42) globulomer.
2. Antistof ifølge krav 1, hvor bindingsaffiniteten af antistoffet til Αβ(20-42) globulomeren er mindst 100, mindst 1000, mindst 10000 eller mindst 100000 større end bindingsaffiniteten af antistoffet til Αβ(1-42) globulomeren.
3. Antistof ifølge krav 1 eller 2, hvor antistoffet binder til Αβ(20-42) globulomeren med med en KD på 1x10'7 M eller større affinitet, med en KD på 1x10'8 M eller større affinitet, med en KD på 1x10'9 M eller større affinitet, med en KD på 1x10'10 M eller større affinitet, eller med en KD på 1x10'11 M eller større affinitet.
4. Antistof ifølge et vilkårligt af kravene 1 til 3, hvor bindingsaffiniteten af antistoffet til Αβ(20-42) globulomeren er større end bindingsaffiniteten af antistoffet til en Αβ(12-42) globulomer.
5. Antistof ifølge krav 4, hvor bindingsaffiniteten af antistoffet til Αβ(20-42) globulomeren er mindst 10, mindst 100, mindst 1000, mindst 10000, eller mindst 100000 gange større end bindingsaffiniteten af antistoffet til Αβ(12-42) globulomeren.
6. Antistof ifølge et vilkårligt af kravene 1 til 5, hvor bindingsaffiniteten af antistoffet til Αβ(20-42) globulomeren er mindst 10, mindst 100, mindst 1000, mindst 10000, eller mindst 100000 gange større end til en Αβ(1-42) monomer.
7. Antistof ifølge et vilkårligt af kravene 1 til 6, hvor antistoffet binder til Αβ(1-42) monomeren med en KD på 1x10'8 M eller mindre affinitet, med en KD på 1x10'7 M eller mindre affinitet, med en KD på 1x10'6 M eller mindre affinitet, eller med en KD på 1x10'5 M eller mindre affinitet.
8. Antistof ifølge et vilkårligt af kravene 1 til 7, hvor bindingsaffiniteten af antistoffet til Αβ(20-42) globulomeren er mindst 10, mindst 100, mindst 1000, mindst 10000, eller mindst 100000 gange større end bindingsaffiniteten af antistoffet til en Αβ(1-40) monomer.
9. Antistof ifølge et vilkårligt af kravene 1 til 8, hvor antistoffet binder til Αβ(1-40) monomeren med en Kd på 1 x10'8 M eller mindre affinitet, med en Kd på 1 x10'7 M eller mindre affinitet, med en KD på 1x10'6 M eller mindre affinitet, eller med en KD på 1x10'5 M eller mindre affinitet.
10. Antistof ifølge et vilkårligt af kravene 1 til 9, hvor bindingsaffiniteten af antistoffet til Αβ(20-42) globulomeren er mindst 10, mindst 100, mindst 1000, mindst 10000, eller mindst 100000 gange større end bindingsaffiniteten af antistoffet til Αβ(1-42) fibriler.
11. Antistof ifølge et vilkårligt af kravene 1 til 10, hvor antistoffet binder til Αβ(1-42) fibriler med en KD på 1x10'8 M eller mindre affinitet, med en KD på 1x10'7 M eller mindre affinitet, med en Kd på 1x10'6 M eller mindre affinitet, eller med en KD på 1x10'5 M eller mindre affinitet.
12. Antistof ifølge et vilkårligt af kravene 1 til 11, hvor bindingsaffiniteten af antistoffet til Αβ(20-42) globulomeren er mindst 10, mindst 100, mindst 1000, mindst 10000, eller mindst 100000 gange større end bindingsaffiniteten af antistoffet til Αβ(1-40) fibriler.
13. Antistof ifølge et vilkårligt af kravene 1 til 12, hvor antistoffet binder til Αβ(1-40) fibriler med en KD på 1x10'8 M eller mindre affinitet, med en KD på 1x10'7 M eller mindre affinitet, med en KD på 1x10'6 M eller mindre affinitet, eller med en KD på 1x10'5 M eller mindre affinitet.
14. Antistof ifølge et vilkårligt af kravene 1 til 13, hvor antistoffet er et rekombi-nant antistof.
15. Antistof ifølge et vilkårligt af kravene 1 til 14, hvor antistoffet er humant eller humaniseret.
16. Antistof ifølge et vilkårligt af kravene 1 til 15, hvor nævnte antistof binder til den samme epitop som et monoklonalt antistof valgt fra gruppen bestående af det monoklonale antistof 5F7 opnåeligt fra en hybridom betegnet af American Type Culture Collection som depotnummer PTA-7241, det monoklonale antistof 10F11 opnåeligt fra en hybridom betegnet af American Type Culture Collection som depotnummer PTA-7239, det monoklonale antistof 7C6 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7240, det monoklonale antistof 4B7 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7242, det monoklonale antistof 2F2 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7408, det monoklonale antistof 6A2 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7409, det monoklonale antistof 4D10 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7405, det monoklonale antistof 7E5 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7809, det monoklonale antistof 10C1 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7810, og det monoklonale antistof 3B10 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7851.
17. Antistof ifølge et vilkårligt af kravene 1 til 16, hvor antistoffet omfatter ami-nosyresekvensen af den tunge kæde CDR3 og/eller aminosyresekvensen af den lette kæde CDR3 fra et monoklonalt antistof valgt fra gruppen bestående af det monoklonale antistof 5F7 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7241, det monoklonale antistof 10F11 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7239, det monoklonale antistof 7C6 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7240, det monoklonale antistof 4B7 opnåeligt fra et hybridom betegnet af Arne- rican Type Culture Collection som depotnummer PTA-7242, det monoklonale antistof 2F2 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7408, det monoklonale antistof 6A2 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7409, det monoklonale antistof 4D10 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7405, det monoklonale antistof 7E5 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7809, det monoklonale antistof 10C1 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7810, og det monoklonale antistof 3B10 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7851.
18. Antistof ifølge krav 17, hvor antistoffet omfatter aminosyresekvensen af den tunge kæde CDR2 og/eller aminosyresekvensen af den lette kæde CDR2 af et monoklonalt antistof valgt fra gruppen bestående af det monoklonale antistof 5F7 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7241, det monoklonale antistof 10F11 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7239, det monoklonale antistof 7C6 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7240, det monoklonale antistof 4B7 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7242, det monoklonale antistof 2F2 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7408, det monoklonale antistof 6A2 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7409, det monoklonale antistof 4D10 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7405, det monoklonale antistof 7E5 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7809, det monoklonale antistof 10C1 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7810, and det monoklonale antistof 3B10 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7851.
19. Antistof ifølge krav 17 eller 18, hvor antistoffet omfatter aminosyresekven-sen af den tunge kæde CDR1 og/eller aminosyresekvensen af den lette kæde CDR1 af et monoklonalt antistof valgt fra gruppen bestående af det monoklona-le antistof 5F7 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7241, det monoklonale antistof 10F11 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7239, det monoklonale antistof 7C6 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7240, det monoklonale antistof 4B7 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7242, det monoklonale antistof 2F2 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7408, det monoklonale antistof 6A2 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7409, det monoklonale antistof 4D10 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7405, det monoklonale antistof 7E5 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7809, det monoklonale antistof 10C1 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7810, and det monoklonale antistof 3B10 opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7851.
20. Antistof ifølge krav 1, hvor antistoffet omfatter mindst en CDR omfattende en aminosyresekvens valgt fra gruppen bestående af: aminosyregrupperne 31-35 i SEQ ID NO:3, aminosyregrupperne 50-66 i SEQ ID NO:3, aminosyregrupperne 99-109 i SEQ ID NO:3, aminosyregrupperne 24-39 i SEQ ID NO:4, aminosyregrupperne 55-61 i SEQ ID NO:4, aminosyregrupperne 94-102 i SEQ ID NO:4, aminosyregrupperne 31-35 i SEQ ID NO:7, aminosyregrupperne 50-66 i SEQ ID NO:7, aminosyregrupperne 97-109 i SEQ ID NO:7, aminosyregrupperne 24-39 i SEQ ID NO:8, aminosyregrupperne 55-61 i SEQ ID NO:8, aminosyregrupperne 94-102 i SEQ ID NO:8, aminosyregrupperne 31-35 i SEQ ID NO:11, aminosyregrupperne 50-65 i SEQ ID NO:11, aminosyregrupperne 98-107 i SEQ ID NO:11, aminosyregrupperne 24-39 i SEQ ID NO:12, aminosyre- grupperne 55-61 i SEQ ID N0:12, aminosyregrupperne 94-102 i SEQ ID NO:12, aminosyregrupperne 31-35 i SEQ ID NO:15, aminosyregrupperne 50-66 i SEQ ID NO:15, aminosyregrupperne 99-107 i SEQ ID NO:15, aminosyregrupperne 24-40 i SEQ ID NO:16, aminosyregrupperne 56-62 i SEQ ID NO:16, aminosyregrupperne 95-103 i SEQ ID NO:16, aminosyregrupperne 31-35 i SEQ ID NO:19, aminosyregrupperne 50-66 i SEQ ID NO:19, aminosyregrupperne 99-109 i SEQ ID NO:19, aminosyregrupperne 24-39 i SEQ ID NO:20, aminosyregrupperne 55-61 i SEQ ID NO:20, aminosyregrupperne 94-102 i SEQ ID NO:20, aminosyregrupperne 31-35 i SEQ ID NO:23, aminosyregrupperne 50-66 i SEQ ID NO:23, aminosyregrupperne 99-109 i SEQ ID NO:23, aminosyregrupperne 24-39 i SEQ ID NO:24, aminosyregrupperne 55-61 i SEQ ID NO:24, aminosyregrupperne 94-102 i SEQ ID NO:24, aminosyregrupperne 31-35 i SEQ ID NO:27, aminosyregrupperne 50-65 i SEQ ID NO:27, aminosyregrupperne 98-101 i SEQ ID NO:27, aminosyregrupperne 24-39 i SEQ ID NO:28, aminosyregrupperne 55-61 i SEQ ID NO:28, aminosyregrupperne 94-102 i SEQ ID NO:28, aminosyregrupperne 31-35 i SEQ ID NO:31, aminosyregrupperne 50-66 i SEQ ID NO:31, aminosyregrupperne 99-107 i SEQ ID NO:31, aminosyregrupperne 24-40 i SEQ ID NO:32, aminosyregrupperne 56-62 i SEQ ID NO:32, aminosyregrupperne 95-103 i SEQ ID NO:32, aminosyregrupperne 31-35 i SEQ ID NO:35, aminosyregrupperne 50-66 i SEQ ID NO:35, aminosyregrupperne 99-107 i SEQ ID NO:35, aminosyregrupperne 24-40 i SEQ ID NO:36, aminosyregrupperne 56-62 i SEQ ID NO:36, aminosyregrupperne 95-103 i SEQ ID NO:36, aminosyregrupperne 31-35 i SEQ ID NO:38, aminosyregrupperne 50-66 i SEQ ID NO:38, og aminosyregrupperne 98-109 i SEQ ID NO:38.
21. Antistof ifølge krav 20, hvor antistoffet omfatter mindst 3 CDR valgt fra et variabelt domæne, hvilke CDR sæt består af:
22. Antistof ifølge krav 1, hvor antistoffet omfatter mindst et variabelt domæne med en aminosyresekvens valgt fra gruppen bestående af: SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:36 og SEQ ID NO:38.
23. Antistof ifølge krav 22 omfattende to variable domæner, hvor nævnte to variable domæner har aminosyresekvenser valgt fra gruppen bestående af: SEQ ID NO:3 & SEQ ID NO:4, SEQ ID NO:7 & SEQ ID NO:8 & SEQ ID NO:11 & SEQ ID NO:12, SEQ ID NO:15 & SEQ ID NO:16, SEQ ID NO:19 & SEQ ID NO:20, SEQ ID NO:23 & SEQ ID NO:24, SEQ ID NO:27 & SEQ ID NO:28, SEQ ID NO:31 & SEQ ID NO:32 og SEQ ID NO:35 & SEQ ID NO:36.
24. Antistof ifølge krav 1, som er valgt fra: monoklonalt antistof (5F7) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7241, monoklonalt antistof (10F11) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7239, monoklonalt antistof (7C6) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7240, monoklonalt antistof (4B7) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7242, monoklonalt antistof (2F2) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7408, monoklonalt antistof (6A2) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7409, monoklonalt antistof (4D10) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7405, monoklonalt antistof (7E5) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7809, monoklonalt antistof (10C1) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7810, og monoklonalt antistof (3B10) opnåeligt fra et hybridom betegnet af American Type Culture Collection som depotnummer PTA-7851.
25. Antigenbindingsgruppe fra et antistof som defineret i et vilkårligt af kravene 1 til 24.
26. Isoleret nucleinsyre, som koder for en antistofaminosyresekvens fra et vilkårligt af kravene 1 til 25.
27. Vektor omfattende en isoleret nucleinsyre ifølge krav 26.
28. Værtscelle omfattende en vektor ifølge krav 27.
29. Værtscelle ifølge krav 28, som er et hybridom betegnet af American Type Culture Collection som depotnummer valgt fra gruppen bestående af PTA-7241, PTA-7239, PTA-7240, PTA-7242, PTA-7408, PTA-7409, PTA-7405, PTA-7809, PTA-7810 og PTA-7851.
30. Fremgangsmåde til fremstilling af et monoklonalt antistof omfattende dyrkning af en værtscelle ifølge krav 28 eller et hybridom ifølge krav 29 i dyrkningsmedie ved betingelser egnede til at fremstille antistoffet.
31. Monoklonalt antistof opnåeligt ved en fremgangsmåde ifølge krav 30.
32. Farmaceutisk sammensætning omfattende et antistof eller en antigenbindingsgruppe som defineret i et vilkårligt af kravene 1 til 25 eller 31 og en farmaceutisk acceptabel bærer.
33. Anvendelse af et antistof eller en antigenbindingsgruppe som defineret i et vilkårligt af kravene 1 til 25 eller 31 til fremstilling afen farmaceutisk sammensætning til behandling eller forebyggelse afen amyloidosis.
34. Anvendelse af et antistof eller en antigenbindingsgruppe som defineret i et vilkårligt af kravene 1 til 25 eller 31 til fremstilling afen sammensætning til diagnosticering afen amyloidosis, såsom Alzheimers syge eller Downs syndrom.
35. Fremgangsmåde til diagnose af en amyloidosis, som omfatter at tilvejebringe en prøve fra patienten mistænkt for at have amyloidosis, såsom Alzheimers syge eller Downs syndrom, bringe prøven i kontakt med et antistof eller en antigenbindingsgruppe eller antigenbindingsgruppen med et antigen som defineret i et vilkårligt af kravene 1 til 25 eller 31, hvor tilstedeværelsen af komplekset indikerer en amyloidosis hos patienten.
DK06818937.2T 2005-11-30 2006-11-30 Anti-A-globulomer-antistoffer, antigenbindingsgrupper deraf, tilsvarende hybridomer, nucleinsyrer, vektorer, værtsceller, fremgangsmåder til fremstilling af nævnte antistoffer, DK1954718T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74086605P 2005-11-30 2005-11-30
US77917106P 2006-03-03 2006-03-03
US78736106P 2006-03-30 2006-03-30
US84240006P 2006-09-05 2006-09-05
PCT/EP2006/011530 WO2007062852A2 (en) 2005-11-30 2006-11-30 ANTI-Aβ GLOBULOMER ANTIBODIES, ANTIGEN-BINDING MOIETIES THEREOF, CORRESPONDING HYBRIDOMAS, NUCLEIC ACIDS, VECTORS, HOST CELLS, METHODS OF PRODUCING SAID ANTIBODIES, COMPOSITIONS COMPRISING SAID ANTIBODIES, USES OF SAID ANTIBODIES AND METHODS OF USING SAID ANTIBODIES

Publications (1)

Publication Number Publication Date
DK1954718T3 true DK1954718T3 (da) 2014-12-15

Family

ID=37744650

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06818937.2T DK1954718T3 (da) 2005-11-30 2006-11-30 Anti-A-globulomer-antistoffer, antigenbindingsgrupper deraf, tilsvarende hybridomer, nucleinsyrer, vektorer, værtsceller, fremgangsmåder til fremstilling af nævnte antistoffer,

Country Status (20)

Country Link
US (3) US8691224B2 (da)
EP (2) EP1954718B1 (da)
JP (3) JP5475994B2 (da)
KR (1) KR20080090408A (da)
CN (2) CN101432302A (da)
AU (1) AU2006319358B2 (da)
BR (1) BRPI0619249A2 (da)
CA (1) CA2628703C (da)
CR (1) CR9969A (da)
DK (1) DK1954718T3 (da)
EC (1) ECSP088462A (da)
ES (2) ES2527661T3 (da)
GT (1) GT200800082A (da)
IL (2) IL191588A0 (da)
NO (1) NO20082890L (da)
PL (2) PL1954718T3 (da)
PT (2) PT1954718E (da)
RU (1) RU2442793C2 (da)
WO (1) WO2007062852A2 (da)
ZA (1) ZA200804346B (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2015111675A (ru) * 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
KR101605207B1 (ko) * 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
EP2238166B1 (en) 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
RU2542967C2 (ru) * 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
WO2009104736A1 (ja) * 2008-02-22 2009-08-27 財団法人ヒューマンサイエンス振興財団 組織アミロイドプラーク親和性抗体及びそれを用いた医薬組成物
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MY159667A (en) 2008-05-09 2017-01-13 Abbvie Inc Antibodies to receptor of advanced glycation end products (rage) and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
RU2010153578A (ru) * 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
NZ593643A (en) 2008-11-25 2013-03-28 Biogen Idec Inc Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
SI2949666T1 (sl) 2008-12-19 2019-03-29 Biogen International Neuroscience Gmbh Človeška anti alfa-sinukleinska protitelesa
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
CN102612374A (zh) 2009-11-12 2012-07-25 霍夫曼-拉罗奇有限公司 提升树突棘密度的方法
SG181563A1 (en) 2009-12-08 2012-07-30 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
CA2796339C (en) * 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
WO2011151833A1 (en) * 2010-06-03 2011-12-08 Ramot At Tel-Aviv University Ltd. Methods of treating diabetes and compositions capable of same
SG187173A1 (en) 2010-07-30 2013-02-28 Ac Immune Sa Safe and functional humanized anti beta-amyloid antibody
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
MY176695A (en) 2012-01-27 2020-08-19 Abbvie Inc Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
EP2900265B1 (en) 2012-09-27 2018-05-30 Biocare Medical, LLC Anti-uroplakin ii antibodies systems and methods
CA2890263C (en) 2012-11-01 2020-03-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US10429390B2 (en) 2012-12-18 2019-10-01 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
JP6445467B2 (ja) * 2013-02-28 2019-01-09 バイオケア メディカル， エルエルシー 抗ｐ４０抗体システムおよび方法
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
WO2015051320A2 (en) 2013-10-03 2015-04-09 Biocare Medical, Llc Anti-sox10 antibody systems and methods
US20160000891A1 (en) * 2014-07-07 2016-01-07 AbbVie Deutschland GmbH & Co. KG IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JP7263320B2 (ja) 2017-08-22 2023-04-24 バイオジェン・エムエイ・インコーポレイテッド 抗ベータアミロイド抗体を含有する医薬組成物
AU2020245031A1 (en) 2019-03-26 2021-10-21 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).

Family Cites Families (733)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500076C3 (de) 1975-01-02 1982-11-18 SCHURA Blutderivate GmbH & Co KG, 4150 Krefeld Verfahren zur Gewinnung von intravenös-verträglichen Gammaglobulinen
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
WO1982001011A1 (en) 1980-09-24 1982-04-01 Corp Cetus Diagnostic method and probe
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526039A (en) 1983-06-23 1985-07-02 The United States Of America As Represented By The Secretary Of Transportation Removable strain gauge fixture and method for measuring accumulated strain in a material
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0229046B1 (fr) 1985-03-30 1994-05-04 BALLIVET, Marc Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5107065A (en) * 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5525339A (en) 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
JPS63240797A (ja) 1986-10-14 1988-10-06 Shin Etsu Chem Co Ltd モノクローナル抗体、その製法およびそれを含有する診断薬
AU611122B2 (en) 1986-11-17 1991-06-06 Scios Nova Inc. Recombinant alzheimer's amyloid protein
DE3702789A1 (de) 1987-01-30 1988-08-18 Bayer Ag Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
JPS63245689A (ja) 1987-03-31 1988-10-12 Suntory Ltd ヒトアミロイド関連蛋白モノクロ−ナル抗体
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
CA1340802C (en) 1987-08-15 1999-10-26 Yasuyuki Takahashi Senile amyloid precursor protein and an antibody specific for the same
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
AU3056289A (en) 1988-01-13 1989-08-11 Mclean Hospital Corporation, The Genetic constructs containing the alzheimer brain amyloid gene
AU3204689A (en) 1988-02-10 1989-09-06 Children's Medical Center Corporation Amyloid protein precursors, genetic probes, antibodies, and methods of use
US5134062A (en) 1988-03-22 1992-07-28 Cornell Research Foundation, Inc. Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
US5015570A (en) 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
US6287793B1 (en) 1988-08-19 2001-09-11 Elan Pharmaceuticals, Inc. Diagnostic methods for alzheimer's disease
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US5234814A (en) 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
EP0415801A1 (en) 1989-07-05 1991-03-06 N.V. Innogenetics S.A. Monoclonal antibodies against activated microglial cells
EP0411974A1 (en) 1989-07-05 1991-02-06 N.V. Innogenetics S.A. Monoclonal antibodies to a neurofibrillary tangle antigen
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
JP2571874B2 (ja) 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7121191A (en) 1990-02-26 1991-10-10 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for alzheimer's disease
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
DE4022247A1 (de) 1990-07-12 1992-01-16 Hoechst Ag Verfahren zur extraktiven abtrennung von 2-alkylthio-5-phenylpyrimidinen aus ihren reaktionsgemischen
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
JPH04252195A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd モノクローナル抗体及びハイブリドーマ
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
JPH04320694A (ja) 1991-04-22 1992-11-11 Ono Pharmaceut Co Ltd ヒトグリア細胞増殖抑制因子に対するモノクローナル抗体
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
JPH04342883A (ja) 1991-05-17 1992-11-30 Sanden Corp 容量可変型斜板式圧縮機
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JP3909084B2 (ja) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
DE69227380T3 (de) 1991-11-12 2007-01-11 Prana Biotechnology Ltd., South Melbourne Verfahren zur bestimmung und behandlung von alzheimer-krankheit
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US20020009443A1 (en) 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
ATE438716T1 (de) 1991-12-06 2009-08-15 Max Planck Gesellschaft Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US20010029293A1 (en) 1992-01-27 2001-10-11 Icos Corporation Icam-related protein
US5538845A (en) 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5912120A (en) 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5455169A (en) 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
TW258789B (da) 1992-09-28 1995-10-01 Rohm & Haas
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US5891623A (en) 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
ZA938243B (en) 1992-11-12 1995-05-04 Hybritech Inc Altered affinity polypeptides of metal chelate binding antibodies
US6010913A (en) * 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
DE69432629T3 (de) 1993-01-25 2008-01-17 Takeda Pharmaceutical Co. Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
JPH09506170A (ja) 1993-10-20 1997-06-17 デューク・ユニヴァーシティ β‐アミロイドペプチドに物質を結合する方法
US5565352A (en) 1993-11-24 1996-10-15 Arch Development Corporation Deubiquitinating enzyme: compositions and methods
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
WO1995016787A1 (en) 1993-12-13 1995-06-22 The Uab Research Foundation Diagnostic tests and reagents for detecting risk of alzheimer's disease and stroke
US6620915B2 (en) 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
US6251395B1 (en) * 1993-12-23 2001-06-26 W. Michael Gallatin Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies
US6432404B1 (en) 1993-12-23 2002-08-13 Icos Corporation Methods of inhibiting locomotor damage following spinal cord injury with α D-specific antibodies
JPH07209295A (ja) 1994-01-10 1995-08-11 Nikken Chem Co Ltd 抗体及び酵素標識抗原並びにこれらを用いる酵素免疫測定法及び測定用キット
JPH07209296A (ja) 1994-01-10 1995-08-11 Nikken Chem Co Ltd 抗原及び酵素標識抗体並びにこれらを用いる酵素免疫測定法及び測定用キット
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
JPH07238096A (ja) 1994-02-25 1995-09-12 S R L:Kk 抗ポリユビキチン・モノクローナル抗体およびポリユビキチンの測定方法
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
JPH07309900A (ja) 1994-05-20 1995-11-28 Idemitsu Kosan Co Ltd 抗ヒトプロカテプシンｂモノクローナル抗体、それを産生するハイブリドーマ及びそれを用いたヒトプロカテプシンｂ又はヒトカテプシンｂの測定方法
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6018021A (en) * 1994-10-19 2000-01-25 The Research Foundation Of State University Of New York Human transaldolase: an autoantigen with a function in metabolism
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
JP3663228B2 (ja) 1995-03-14 2005-06-22 株式会社医学生物学研究所 ニューロプシンに対する抗体
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5705330A (en) * 1995-04-14 1998-01-06 Abbott Laboratories Chemiluminescent immunoassay for antibody detection
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
EP0826034A4 (en) 1995-04-21 2002-06-19 Cell Genesys Inc PRODUCTION OF LARGE GENOMIC DNA DELETIONS
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5712158A (en) 1995-06-06 1998-01-27 Warner-Lambert Company Cell line for the rapid expression of functional calcium channels
US6717031B2 (en) * 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
WO1996040731A1 (en) 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
JP3767755B2 (ja) 1995-06-23 2006-04-19 エーザイ株式会社 抗ｊｃウイルス抗体
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP0850051A2 (en) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
JP3495738B2 (ja) 1995-09-14 2004-02-09 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 天然ＰｒＰｓｃ特異的抗体
FR2740454B1 (fr) 1995-10-26 1997-11-21 Rhone Poulenc Rorer Sa Peptides capables d'inhiber l'endocytose de l'app et sequences nucleotidiques correspondantes
AUPN649395A0 (en) 1995-11-10 1995-12-07 Ramsay Health Care Pty Ltd A method for diagnosing alzheimer's disease
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
KR19980702156A (ko) 1995-12-12 1998-07-15 히라따 다다시 신규 dna, 신규 폴리펩티드 및 신규 항체
JPH09178743A (ja) 1995-12-27 1997-07-11 Oriental Yeast Co Ltd 可溶性ａｐｐの定量法
ES2176523T3 (es) 1996-01-19 2002-12-01 Res Corp Technologies Inc Procedimiento para la deteccion de la enfermedad de alzheimer.
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU733853B2 (en) 1996-01-30 2001-05-31 Scripps Research Institute, The A G protein-coupled receptor with an enlarged extracellular domain
RU2270030C2 (ru) 1996-02-09 2006-02-20 Абботт Байотекнолоджи эЛтиди. СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ЧЕЛОВЕЧЕСКОГО TNFα (ВАРИАНТЫ), ПРИМЕНЕНИЕ ВЫДЕЛЕННОГО АНТИТЕЛА ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА В КАЧЕСТВЕ КОМПОНЕНТА ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА (ВАРИАНТЫ) И ВЫДЕЛЕННОЕ ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1997046678A1 (en) 1996-06-06 1997-12-11 Bayer Corporation Nucleic acids and polypeptides related to presenilin
IL128416A (en) * 1996-08-13 2004-06-01 Gerolymatos P N Sa Use of Clioquinol for the preparation of a pharmaceutical preparation for the treatment of Alzheimer's disease and pharmaceutical preparations containing it
WO1999009150A1 (en) 1996-08-15 1999-02-25 Bayer Corporation Method of introducing modifications into a gene
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US7521531B2 (en) 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
JPH1075781A (ja) 1996-08-30 1998-03-24 Sumitomo Electric Ind Ltd ヒトプロテアソームサブユニットｐ５８蛋白質及びそれに特異的な抗体
EP0834561A1 (en) 1996-09-27 1998-04-08 Rijksuniversiteit te Leiden A gene related to migraine in man
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US5919687A (en) 1996-12-24 1999-07-06 John Hopkins University Recombinant N-SMases and nucleic acids encoding same
PT954282E (pt) 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
WO1998031700A1 (en) 1997-01-21 1998-07-23 The General Hospital Corporation Selection of proteins using rna-protein fusions
JPH10210982A (ja) 1997-01-31 1998-08-11 Fuji Yakuhin Kogyo Kk 新規なタンパク質
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
DK2283834T3 (da) 1997-03-17 2016-08-15 Btg Int Ltd Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf
WO1998047343A2 (en) 1997-04-04 1998-10-29 Biosite Diagnostics, Inc. Antibodies or binding protein libraries displayed on phage, cells, or other replicatable genetic packages
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
AU7171098A (en) 1997-05-01 1998-11-24 Board Of Regents, The University Of Texas System Directed evolution of enzymes and antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
PT1860187E (pt) 1997-05-15 2011-10-04 Genentech Inc Receptor apo-2
US6689359B1 (en) 1997-07-21 2004-02-10 Arpi Matossian-Rogers Ligands, including antibodies, showing reactivity against endocrine cells
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
PT1049712E (pt) 1997-08-14 2007-04-30 Pasteur Institut Proteínas híbridas da toxina do tétano que migram retrogradamente e trans - sinapticamente para o snc
US7923216B2 (en) 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
JP2001513576A (ja) 1997-08-26 2001-09-04 グリアテック インコーポレイテッド 側副経路を介する補体活性化を阻害するためのプロセス
US6666935B1 (en) 1997-09-09 2003-12-23 The Regents Of The University Of California Sol-gel manufactured energetic materials
FR2768346B1 (fr) 1997-09-15 2002-04-19 Fond Jean Dausset Ceph Compose assurant l'inhibition de la preseniline 1 pour la preparation d'un medicament et agent de diagnostic
US20040185039A1 (en) 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999022024A1 (en) 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Detection of neurodegenerative diseases
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
EP1033998B1 (en) 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease
CA2314909A1 (en) 1997-12-15 1999-06-24 Kyowa Hakko Kogyo Co., Ltd. Human nap1 protein
US6730778B2 (en) 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
EP1054664B1 (en) 1998-02-11 2012-08-08 BHI Limited Partnership Method for modulating macrophage activation
JP2002505097A (ja) 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
US20050112543A1 (en) 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6913756B1 (en) 1998-04-29 2005-07-05 The Uab Research Foundation Monoclonal antibodies specific for anthrax and peptides derived from the antibodies thereof
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
WO1999058157A1 (en) 1998-05-08 1999-11-18 Cramer Donald V Method for inhibiting antibody-mediated rejection of xenogeneic tissues
EP1077690A1 (en) 1998-05-15 2001-02-28 Neurochem, Inc. Use of amyloid inhibitors for modulating neuronal cell death
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
JP2000050885A (ja) 1998-06-02 2000-02-22 Fuji Chemical Industries Ltd カテプシンに対する抗体およびそれらの利用
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AU755340B2 (en) 1998-07-02 2002-12-12 Fuso Pharmaceutical Industries, Ltd. Serine protease-specific monoclonal antibody and utilization thereof
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US7375184B2 (en) 1998-09-01 2008-05-20 Genentech, Inc. PRO1382 polypeptides
ATE346923T1 (de) 1998-09-17 2006-12-15 Otsuka Pharma Co Ltd Ly6h-gen
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
AU5999199A (en) 1998-09-29 2000-04-17 Kyowa Hakko Kogyo Co. Ltd. Novel antibodies, drugs containing these antibodies and methods for screening compounds by using these antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1731913A3 (en) 1998-12-02 2007-01-17 The Trustees Of The University Of Pennsylvania Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
EP1135519A4 (en) 1998-12-02 2004-11-24 Univ Pennsylvania METHODS AND COMPOSITIONS FOR DETERMINING LIPID PEROXIDATION IN OXIDANT STRESS-RELATED SYNDROMES AND DISEASES
ES2304811T3 (es) 1998-12-14 2008-10-16 University Of Miami Fragmentos del factor de crecimiento de tejido conjuntivo.
KR100856446B1 (ko) 1998-12-23 2008-09-04 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
DE19902550A1 (de) 1999-01-22 2000-07-27 Memorec Medical Molecular Rese Aspartatprotease
US20030185826A1 (en) 1999-02-24 2003-10-02 Tobinick Edward L. Cytokine antagonists for the treatment of localized disorders
KR101222450B1 (ko) 1999-03-25 2013-01-16 애보트 게엠베하 운트 콤파니 카게 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법
FR2791263B1 (fr) 1999-03-26 2001-04-27 Halina Zofia Malina Preparations des medicaments bases sur une reponse immunitaire contre l'accumulation de proteines modifiees par l'acide xanthurenique
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AR024558A1 (es) 1999-06-01 2002-10-16 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
US20030082554A1 (en) 1999-06-03 2003-05-01 Curagen Corporation Novel nucleic acid sequences encoding human cell adhesion molecule protein-like polypeptides
JP2000354487A (ja) 1999-06-15 2000-12-26 Takashi Muramatsu ミッドカイン受容体
US20020002270A1 (en) 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
ES2312348T3 (es) 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP2829609A1 (en) 1999-08-24 2015-01-28 E. R. Squibb & Sons, L.L.C. Human CTLA-4 antibodies and their uses
EP1210464B1 (en) 1999-09-01 2004-11-24 EVOTEC Neurosciences GmbH Methods of diagnosing or prognosticating age-related macular degeneration
EP1180938B1 (en) 1999-09-03 2010-03-24 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents, compositions and methods utilizing the same useful in treating or preventing alzheimer disease
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
JP2001122900A (ja) 1999-10-21 2001-05-08 Yasukazu Tanuma 抗−ＤＮａｓｅγ抗体並びにその製造及び使用
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
US20070135337A2 (en) 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
NZ540564A (en) 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
CA2393763A1 (en) 1999-12-08 2001-06-14 Mindset Biopharmaceuticals (Usa), Inc. Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
EP1752472A3 (en) 1999-12-08 2007-04-25 Intellect Neurosciences, Inc. Chimeric amyloid beta peptides
JP2001231578A (ja) 1999-12-09 2001-08-28 Kyowa Hakko Kogyo Co Ltd Ｉｌ−１ファミリーに属する蛋白質
BR0016652A (pt) 1999-12-23 2002-11-19 Neurochem Inc Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
US20030077757A1 (en) 2000-01-11 2003-04-24 Andrews William H. Method of treating aging-related disorders
US6785434B2 (en) 2000-01-17 2004-08-31 Avanex Corporation Attenuator integrated with modulator and transmitting module for WDM systems using the same
US6806254B2 (en) 2000-02-03 2004-10-19 Nuvelo, Inc. Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
CZ20022748A3 (cs) 2000-02-21 2004-03-17 Pharmexa A/S Nová metoda regulace obsahu amyloidu
JP5025871B2 (ja) 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
TR200202799T3 (tr) * 2000-02-24 2003-03-21 Washington University St.Louis AB peptidini sekanslayan insanlaştırılmış antikorlar
EP1130032A1 (en) 2000-02-28 2001-09-05 Gesellschaft für biotechnologische Forschung mbH (GBF) Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR)
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001071351A1 (en) * 2000-03-22 2001-09-27 The General Hospital Corporation Method for treatment of neurodegenerative diseases
US6664442B2 (en) 2000-03-30 2003-12-16 Elan Pharmaceuticals, Inc. Selecting compounds to reduce inflammation associated with Alzheimer's disease
AU2001249835A1 (en) * 2000-04-03 2001-10-15 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
US7371365B2 (en) 2000-04-04 2008-05-13 Mayo Foundation For Medical Education And Research Methods for detecting parenchymal plaques in vivo
AUPQ712000A0 (en) 2000-04-27 2000-05-18 Medvet Science Pty. Ltd. Antigenic peptide fragments of VapA protein, and uses thereof
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
CA2407956A1 (en) 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
DE60108111T2 (de) 2000-05-22 2005-12-08 New York University Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate
ATE446366T1 (de) * 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
JP4252195B2 (ja) 2000-06-27 2009-04-08 新日本無線株式会社 高周波線路の変換器
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
CA2413354C (en) 2000-06-28 2014-04-01 Prana Biotechnology Limited Neurotoxic a.beta. oligomers in alzheimer's disease
US6686449B2 (en) * 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
JP2004502427A (ja) 2000-07-06 2004-01-29 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 異常アルツハイマー病病理と関連する新規ａｐｐ突然変異
AU2007200047B2 (en) 2000-07-07 2009-11-26 Bioarctic Neuroscience Ab Prevention and treatment of Alzheimer's disease
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US6524819B1 (en) 2000-07-11 2003-02-25 Incyte Genomics, Inc. Down syndrome critical region 1-like proteins
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en) 2000-07-12 2002-01-16 Richard Dr. Dodel Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
JP2002040023A (ja) 2000-07-28 2002-02-06 Mitsubishi Chemicals Corp アルツハイマー病の検出方法
US20070009931A1 (en) * 2000-08-04 2007-01-11 Kirsch Wolff M Negative correlation between IRP-2 and Transferrin receptor expression as a diagnostic of Alzheimer's disease
JP5153986B2 (ja) 2000-09-06 2013-02-27 アベンティス・ファーマ・ソシエテ・アノニム アミロイドーシスと関連する疾患のための方法及び組成物
GB0024446D0 (en) 2000-10-05 2000-11-22 Glaxo Group Ltd Protein
IT1319277B1 (it) 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
CA2360219A1 (en) 2000-10-27 2002-04-27 Mount Sinai Hospital Method for detecting alzheimer's disease
EP1538163A3 (en) 2000-11-01 2005-06-15 Insight Biotechnology Limited Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease
DE10055703A1 (de) 2000-11-02 2002-05-08 Peter F Pascoe Verhinderung der Zellzerstörung und Beseitigung sklrotischer Amyloide verursacht durch organspezifische Antikörperaggregate
WO2002094870A2 (en) 2000-11-02 2002-11-28 Curagen Corporation Proteins and nucleic acids encoding same
WO2002035987A2 (en) 2000-11-03 2002-05-10 Massachusetts Institute Of Technology METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20020133001A1 (en) 2000-11-27 2002-09-19 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
GB0100110D0 (en) 2001-01-04 2001-02-14 Univ Leeds Modulation of calcium channel activity
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
US20020132758A1 (en) 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20040191264A1 (en) 2001-02-19 2004-09-30 Nielsen Klaus Gregorius Synthetic vaccine agents
JP4659236B2 (ja) 2001-03-01 2011-03-30 大塚製薬株式会社 細胞傷害活性の測定法
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
FR2822238B1 (fr) * 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
CA2443770A1 (en) 2001-04-23 2002-10-31 Curagen Corporation Proteins and nucleic acids encoding same
US6451547B1 (en) 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
DE60229051D1 (de) * 2001-04-30 2008-11-06 Lilly Co Eli Humanisierte antikörper
US7196163B2 (en) * 2001-05-22 2007-03-27 Merk & Co., Inc. Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity
EP1990057A1 (en) 2001-05-22 2008-11-12 Merck & Co., Inc. Beta-secretase substrates and uses thereof
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
ATE277952T1 (de) 2001-06-12 2004-10-15 Wiltfang Jens Monoklonaler antikörper, mbab 1e8, welcher für die zwei ersten n-terminalen aminosäuren von amyloid-beta-peptiden spezifisch ist und dessen verwendung zum nachweis von amyloid-beta peptiden und/oder sappa
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CN100497389C (zh) 2001-06-13 2009-06-10 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
US7094884B2 (en) 2001-06-22 2006-08-22 Roche Diagnostics Corporation Soluble complexes of amylod β peptide and peptidyl prolyl isomerase chaperone and methods of making and using them
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
CN1396183A (zh) 2001-07-13 2003-02-12 张小如 降低脑内与老年痴呆有关的淀粉样变纤维的融合人抗体
AU2002326412A1 (en) 2001-07-20 2003-03-03 Oregon Health And Science University Novel human nucleic acids encoding a pantothenate kinase and methods of use
JP4729717B2 (ja) 2001-08-03 2011-07-20 株式会社医学生物学研究所 ＧＭ１ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするＤＮＡ
JP4320694B2 (ja) 2001-08-08 2009-08-26 株式会社オーク製作所 多重露光描画装置および多重露光式描画方法
EP1424892A4 (en) 2001-08-10 2006-08-23 Univ South Florida MODULATION OF ANGIOGENESIS BY A-BETA PEPTIDES
DK1944040T3 (da) 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
US20060073149A1 (en) 2001-08-17 2006-04-06 Bales Kelly R Rapid improvement of cognition in condition related to abeta
WO2003016467A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
JP4511830B2 (ja) 2001-08-17 2010-07-28 ワシントン・ユニバーシティ アルツハイマー病のアッセイ方法
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
EP1438400B1 (en) 2001-10-01 2009-06-17 Dyax Corp. Multi-chain eukaryotic display vectors and uses thereof
SG121733A1 (en) 2001-10-03 2006-05-26 Pfizer Prod Inc Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
DE60225821T2 (de) 2001-10-04 2009-04-30 Immuno-Biological Laboratories Co., Ltd., Takasaki Reagens zum Nachweis eines Risikofaktors der Alzheimer-Krankheit, Nachweiskit dafür und Verfahren zum Nachweis eines Risikofaktors der Alzheimer-Krankheit unter ihrer Verwendung
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
GB0124317D0 (en) 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
CN100488982C (zh) 2001-11-02 2009-05-20 迪尔基因国际有限公司 与β-淀粉样蛋白结合并引起蛋白质构象转变的单克隆抗体的制备方法
EP1572894B1 (en) 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US7179606B2 (en) * 2001-11-23 2007-02-20 Syn X Pharma, Inc. IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
US7026129B2 (en) 2001-11-23 2006-04-11 Syn X Pharma, Inc. IG lambda biopolymer markers predictive of Alzheimers disease
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
WO2003046012A1 (en) 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation
AU2002353485B2 (en) 2001-12-04 2009-01-15 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
US20050227941A1 (en) 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
US20070128191A1 (en) 2001-12-26 2007-06-07 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20050153381A1 (en) 2002-02-14 2005-07-14 Marusich Michael F. Immunocapture of mitochondrial protein complexes
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
AU2003213718A1 (en) 2002-03-01 2003-09-16 Szu-Yi Chou Method of producing antigens
DE10208812A1 (de) 2002-03-01 2003-09-11 Basf Plant Science Gmbh Verfahren zur Herstellung von ungesättigten Fettsäuren
US7494655B2 (en) 2002-03-05 2009-02-24 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the β-secretase cleavage site of amyloid precursor protein
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
AU2003226356A1 (en) 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP2330113B1 (en) 2002-04-19 2016-06-29 The Governing Council Of The University Of Toronto Immunological methods and compositions for the treatment of Alzheimer's disease
EP1497661B1 (en) 2002-04-24 2009-11-25 EVOTEC Neurosciences GmbH Diagnostic use of ensadin-0477 gene and protein for neurodegenerative diseases
CA2483729A1 (en) 2002-04-25 2003-11-06 Eli Lilly And Company Method for treating anxiety and mood disorders in older subjects
US20060257420A1 (en) 2002-04-26 2006-11-16 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
DE10221052A1 (de) 2002-05-10 2003-12-04 Transmit Technologietransfer Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten
AU2003243058A1 (en) 2002-05-27 2003-12-12 Bioceros B.V. Methods for using the cd163 pathway for modulating an immune response
AU2003241131A1 (en) 2002-06-14 2003-12-31 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
WO2004001422A2 (en) 2002-06-20 2003-12-31 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2004003563A2 (en) 2002-06-27 2004-01-08 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
PT1517921E (pt) 2002-06-28 2006-09-29 Domantis Ltd Ligandos duplamente especificos com semi-vida no soro aumentada
DK1521831T3 (da) 2002-07-12 2008-06-30 Axon Neuroscience Transgent dyr der udtrykker trunkeret alzheimers tauprotein
US20040091945A1 (en) 2002-07-17 2004-05-13 Cheryl Fitzer-Attas Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease
WO2004009617A1 (ja) 2002-07-18 2004-01-29 Osaka Industrial Promotion Organization Ｎｏｔｃｈ由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬
CA2492930C (en) 2002-07-19 2013-01-08 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
AU2003267999B2 (en) 2002-07-19 2010-03-11 Abbvie Biotechnology Ltd Treatment of TNFalpha related disorders
US7250551B2 (en) * 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
EP1911765A3 (en) 2002-07-24 2008-04-23 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
SE0202880D0 (sv) 2002-07-26 2002-09-30 Wieslab Ab Complement system deficiency assay
ATE422671T1 (de) 2002-07-30 2009-02-15 David Gladstone Inst Verfahren zur diagnose von morbus alzheimer
US20040138296A1 (en) 2002-08-12 2004-07-15 Pharmacia Corporation Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
WO2004014296A2 (en) 2002-08-13 2004-02-19 U.S. Department Of Veterans Affairs Method of detecting and preventing alzheimer’s disease, particularly at prodromal and early stages
EP1535930B1 (en) 2002-08-14 2010-10-06 Mitsubishi Chemical Medience Corporation Antibody specific to central nervous system tau protein
WO2004018997A2 (en) 2002-08-20 2004-03-04 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
WO2004019045A2 (en) 2002-08-23 2004-03-04 Proteosys Ag Method for the diagnosis of alzheimer disease
WO2005025516A2 (en) 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
ATE506072T1 (de) 2002-09-12 2011-05-15 Univ California Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz
US20070010657A1 (en) * 2002-09-13 2007-01-11 Rainer Klocke Cytoplasmic dynein heavy chain 1 genes, expression products, non-human animal model uses in human neurological diseases
US7238488B2 (en) * 2002-09-13 2007-07-03 Grace Maresh Therapeutic and diagnostic applications of perlecan domain I splice variants
EP1558268A4 (en) 2002-09-17 2008-09-17 Univ New York METHODS FOR TREATING AGE-RELATED MEMORY ALTERATIONS (AAMI), LIGHT COGNITIVE DEFICITS (MCI) AND DEMENTIA USING CELL CYCLE INHIBITORS
JP4242128B2 (ja) 2002-09-18 2009-03-18 武田薬品工業株式会社 脳アミロイドーシス予防・治療薬のスクリーニング方法
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20070213512A1 (en) 2002-10-01 2007-09-13 Krafft Grant A Amyloid beta peptide analogs and assemblies thereof
WO2004031400A2 (en) 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
WO2004031241A1 (ja) 2002-10-04 2004-04-15 Techno Network Shikoku Co., Ltd. ズブチリシン様プロプロテインコンベルターゼ・ｐａｃｅ４に対するモノクローナル抗体及びその利用
AU2003282575A1 (en) 2002-10-09 2004-05-04 Activx Biosciences, Inc. Activity-based probes, and methods of their preparation and use
CA2501945A1 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AU2003279312A1 (en) 2002-10-24 2004-05-13 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
WO2004043989A2 (en) 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
US7964194B2 (en) 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
US20040162414A1 (en) 2002-11-22 2004-08-19 Santora Ling C. Method for reducing or preventing modification of a polypeptide in solution
CN100450551C (zh) 2002-11-29 2009-01-14 中国医学科学院基础医学研究所 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
AU2003298799A1 (en) 2002-12-02 2004-06-23 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
US20070010435A1 (en) 2002-12-19 2007-01-11 New York University Method for treating amyloid disease
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2006525226A (ja) 2002-12-24 2006-11-09 ニューロケム （インターナショナル） リミテッド β−アミロイド関連疾患の治療のための治療用製剤
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
US7662380B2 (en) 2003-01-22 2010-02-16 Takeda Pharmaceutical Company Limited ZAQ ligand-1 antibodies and uses thereof
WO2004065569A2 (en) 2003-01-23 2004-08-05 The Regents Of The University Of California Multi-functional antibodies
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR20050118669A (ko) 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US20040242845A1 (en) 2003-02-21 2004-12-02 Nicolau Yves Claude Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
DE10307603A1 (de) 2003-02-22 2004-09-02 Rieter Ingolstadt Spinnereimaschinenbau Ag Textilmaschine
US20060188951A1 (en) 2003-02-24 2006-08-24 In Hee Mook Method for measuring the level of anti-beta-amyloid antibody in body fluids and diagnostic kit for alzheimer's disease using same
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
WO2004085712A2 (en) 2003-03-24 2004-10-07 Penn State Research Foundation Multi-functional polymeric materials and their uses
EP1615946B1 (en) 2003-03-26 2020-05-06 Sudhir Paul Proteolytic and covalent antibodies
WO2005028511A2 (en) 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
CN1189210C (zh) 2003-03-28 2005-02-16 万选才 Cb与生物活性多肽的偶联物及其医药用途
WO2004087733A2 (en) 2003-03-28 2004-10-14 New York University Prevention and treatment of alzheimer amyloid deposition
CA2522067C (en) 2003-04-09 2010-07-06 Canadian Blood Services Detection, characterization and treatment of viral infection and methods thereof
EP1469312A1 (en) 2003-04-18 2004-10-20 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis of Alzheimer's disease
AU2003276107A1 (en) 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
EP1633316A4 (en) 2003-05-06 2008-04-02 Human Genome Sciences Inc ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS
US20040223912A1 (en) 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
ES2246105B1 (es) 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
WO2005018536A2 (en) 2003-05-23 2005-03-03 Human Genome Sciences, Inc. Agonist antibodies that specifically bind the glucagon like peptide-1 receptor
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2004294893A1 (en) 2003-06-06 2005-06-16 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
US7892751B2 (en) 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
RU2006101702A (ru) 2003-06-23 2006-09-10 Дженетикс Инститьют, Ллс (Us) Антитела против интерлейкина-22 и их применения
JP5137400B2 (ja) * 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
DE602004023510D1 (de) 2003-07-15 2009-11-19 Ono Pharmaceutical Co Verzweigte carbonsäureverbindung und deren verwendung
WO2005012330A2 (en) 2003-07-30 2005-02-10 Brigham And Women's Hospital, Inc. AMYLOID β-PEPTIDE AND METHODS OF USE
WO2005011599A2 (en) 2003-08-01 2005-02-10 Northwestern University Antibodies specific for toxic amyloid beta protein oligomers
AU2004263538B2 (en) 2003-08-08 2009-09-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
JP4239750B2 (ja) * 2003-08-13 2009-03-18 セイコーエプソン株式会社 マイクロレンズ及びマイクロレンズの製造方法、光学装置、光伝送装置、レーザプリンタ用ヘッド、並びにレーザプリンタ
WO2005018424A2 (en) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
EP1660534A2 (en) * 2003-08-22 2006-05-31 MedImmune, Inc. Humanization of antibodies
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
EP1516930A1 (en) 2003-09-16 2005-03-23 Georg-August Universität Göttingen Cellular model of tauopathies for lead identification and drug discovery
WO2005027965A1 (en) 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
PT1678209E (pt) 2003-10-07 2011-06-30 Yeda Res & Dev Anticorpos para a nik, a sua preparação e a sua utilização
WO2005037209A2 (en) 2003-10-14 2005-04-28 University Of South Florida A method for the separation anti-amyloid beta antibody with amyloid beta peptide
CN1867828B (zh) 2003-10-15 2010-09-29 第一化学药品株式会社 脂连蛋白多聚体的分离测定方法
WO2005041650A1 (en) 2003-10-20 2005-05-12 Envivo Pharmaceuticals, Inc. TRANSGENIC FLIES EXPRESSING MUTANT Aβ42
WO2005040212A2 (en) 2003-10-24 2005-05-06 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Orthogonal gene switches
ATE447412T1 (de) 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
EP1690870B1 (en) 2003-11-05 2012-03-28 Immuno-Biological Laboratories Co., Ltd. Marker peptide for alzheimer's disease
CA2545152A1 (en) 2003-11-07 2005-05-26 Howard J. Federoff Compositions and methods of treating neurological diseases
JP4796967B2 (ja) 2003-11-07 2011-10-19 ヴァーミリオン インコーポレイテッド アルツハイマー病のためのバイオマーカー
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
KR100556660B1 (ko) * 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
US20050226863A1 (en) 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
UY28641A1 (es) 2003-11-28 2005-06-30 Astrazeneca Ab Anticuerpos
JP4870348B2 (ja) 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
PL1691837T3 (pl) 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
PT1701968E (pt) 2003-12-17 2015-09-11 Wyeth Llc Conjugados de transportadores de péptidos imunogénicos e métodos para produzir os mesmos
WO2005061544A2 (en) * 2003-12-22 2005-07-07 Glaxo Group Limited Nogo-a neutralising immunoglobulins for treatment of neurological diseases
WO2005070965A2 (en) 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Pharmaceutical compositions containing antagonists to lrp4, lrp8 or megalin for treatment of diseases
US20070172496A1 (en) 2004-01-28 2007-07-26 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
WO2005080986A1 (en) 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
EP1717250A4 (en) 2004-02-20 2008-10-01 Immuno Biological Lab Co Ltd MONOCLONAL ANTIBODY AND ITS USE
EA009872B1 (ru) 2004-02-23 2008-04-28 Эли Лилли Энд Компани АНТИ-Aβ АНТИТЕЛА
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
WO2005090971A1 (en) 2004-03-18 2005-09-29 Applied Research Systems Ars Holding N.V. Anti-lipid rafts antibodies
CN1314805C (zh) 2004-03-26 2007-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 一种新型促细胞凋亡素（apo）及其抗体，制备及用途
AU2005229457B2 (en) 2004-03-30 2010-11-25 Glaxo Group Limited Immunoglobulins
EP1743170A2 (en) 2004-04-02 2007-01-17 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US20060099211A1 (en) 2004-04-12 2006-05-11 Carmen Monthe Safer, more potent human immunoglobulin preparations for treating Alzheimer's disease
EP1755605A2 (en) 2004-04-15 2007-02-28 Samaritan Pharmaceuticals, Inc. Use of (4-alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
AU2005233387B2 (en) 2004-04-15 2011-05-26 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
WO2005105998A1 (ja) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
US20080306074A1 (en) 2004-05-14 2008-12-11 Lacor Pascale N Compositions Comprising Addl Receptors, Related Compositions, and Related Methods
GR1005016B (el) 2004-05-14 2005-10-11 BIOMENTIKA@ΛΑΙΦ@ΣΑΙΕΝΣΙΣ@ΑΝΩΝΥΜΗ@ΕΤΑΙΡΕΙΑ@ΦΑΡΜΑΚΕΥΑΤΙΚΩΝ@ΠΡΟΙΟΝΤΩΝ@(συμμετέχει@σε@ποσοστό@50%)@Α ΑΝΑΠΤΥΞΗ ΑΝΤΙΣΩΜΑΤΩΝ IgG KAI IgY ΕΝΑΝΤΙΟΝ ΕΙΔΙΚΟΥ ΣΥΝΘΕΤΙΚΟΥ ΕΠΙΤΟΠΙΚΟΥ ΠΑΡΑΓΩΓΟΥ ΤΗΣ HUMANIN (24-ΠΕΠΤΙΔΙΟΥ ΣΧΕΤΙΖΟΜΕΝΟΥ ΜΕ ΤΗ ΝΟΣΟ ALZHEIMER) ΙΚΑΝΩΝ ΝΑ ΑΝΙΧΝΕΥΟΥΝ ΤΟ ΒΙΟΔΡΑΣΤΙΚΟ 24-ΠΕΠΤΙΔΙΟ.
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
US20060018896A1 (en) 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
US20050276806A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of autism
WO2006033688A2 (en) 2004-06-18 2006-03-30 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-lympho- plus anti-monocytes globulin preparation for inhibiting immune responses
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
WO2006014478A1 (en) 2004-07-02 2006-02-09 Northwestern University MONOLOCAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID β (ABETA)
WO2006005588A1 (en) 2004-07-12 2006-01-19 Geneprot, Inc. Polypeptide species useful for the treatment of neurological disorders
CN1721437A (zh) 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
WO2006006172A2 (en) 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
WO2006014638A2 (en) 2004-07-19 2006-02-09 The General Hospital Corporation ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
ES2306200T3 (es) 2004-07-28 2008-11-01 Schering Corporation Inhibidores macrociclicos de beta-secretasa.
EA016357B1 (ru) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
CA2575190A1 (en) 2004-08-09 2006-02-16 Cellzome Ag Treatment of neurodegenerative diseases by the use of scd4 inhibitors
EP1787998A4 (en) 2004-08-11 2008-08-27 Mitsubishi Chem Corp ANTIBODIES AND USE RELATING THERETO
EP1776591B1 (en) 2004-08-11 2013-10-16 Evotec International GmbH Diagnostic and therapeutic use of a plasma membrane atpase
DE102004039326A1 (de) 2004-08-12 2006-02-16 Abbott Gmbh & Co. Kg Neue medizinische Verwendungen und Verfahren
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
WO2006039470A2 (en) 2004-09-29 2006-04-13 Centocor, Inc. Anti- amyloid antibodies, compositions, methods and uses
WO2006039327A2 (en) 2004-10-01 2006-04-13 Merck & Co., Inc. Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
JP2008520186A (ja) 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
AU2005294373B2 (en) 2004-10-05 2011-12-08 Janssen Alzheimer Immunotherapy Methods and compositions for improving recombinant protein production
JP4776544B2 (ja) 2004-10-06 2011-09-21 啓 森 変異型アミロイドタンパク質
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US20080044356A1 (en) * 2004-10-22 2008-02-21 Regents Of The University Of Minnesota Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof
WO2006055178A2 (en) 2004-10-25 2006-05-26 Merck & Co., Inc. Anti-addl antibodies and uses thereof
US20060160161A1 (en) 2004-10-26 2006-07-20 Elan Pharmaceuticals, Inc. Methods for assessing antibodies to neurodegenerative disease-associated antigens
WO2006050041A2 (en) 2004-10-28 2006-05-11 Ramot At Tel Aviv University Ltd. Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis
US20080199879A1 (en) 2004-10-28 2008-08-21 Sanko Junyaku Co., Ltd. Method of Assaying Alzheimer's Disease and Diagnostic Reagent
EP1836496A2 (en) 2004-11-08 2007-09-26 Nanobac Life Sciences Methods and compositions for protein-hydroxy apatite complexes and their application in testing and modulating immunological system including a novel in vitro test for the detection of antibodies against calcium binding protein-hydroxy apatite complexes
US7709208B2 (en) 2004-11-08 2010-05-04 New York University Methods for diagnosis of major depressive disorder
CN1772766A (zh) 2004-11-12 2006-05-17 中国科学院上海生命科学研究院 抗细胞凋亡相关乙酰胆碱酯酶单克隆抗体及其用途
US20060189582A1 (en) 2004-11-17 2006-08-24 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
PE20061401A1 (es) 2004-12-15 2006-12-23 Neuralab Ltd ANTICUERPOS Aß PARA MEJORAR LA COGNICION
WO2006066233A1 (en) 2004-12-15 2006-06-22 Neuralab Limited An immunoprecipitation-based assay for predicting in vivo efficacy of beta-amyloid antibodies
WO2006066118A2 (en) 2004-12-15 2006-06-22 Neuralab Limited Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment
JP2006166879A (ja) 2004-12-20 2006-06-29 Japan Health Science Foundation Ａｂ−ｄｉｐ、並びにアルツハイマー病の予防及び治療剤
GB0428084D0 (en) * 2004-12-22 2005-01-26 Nokia Corp Method for producing authentication information
WO2006067792A2 (en) 2004-12-22 2006-06-29 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Aldolase autoantigens useful in diagnosis and treatment of alzheimer's disease
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1676859A1 (en) 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
CA2593846A1 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
JP2006213621A (ja) 2005-02-02 2006-08-17 Japan Health Science Foundation Ａｄｏｐｌｉｎタンパク質、およびその利用
US7790363B2 (en) 2005-02-07 2010-09-07 Abbott Laboratories Inc. Diagnostic test for vitamin B12
US20070082350A1 (en) 2005-02-09 2007-04-12 Philip Landfield Assay and method for diagnosing and treating alzheimer's disease
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
GB0503434D0 (en) 2005-02-18 2005-03-30 Senexis Ltd Amyloid-binding peptides, analogues and uses thereof
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
AU2006220709B2 (en) 2005-03-04 2012-09-06 Biogen Ma Inc. Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
AU2006222193B2 (en) * 2005-03-05 2011-11-17 AbbVie Deutschland GmbH & Co. KG Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies
JP2008537543A (ja) 2005-03-07 2008-09-18 ノバルティス アクチエンゲゼルシャフト 神経変性状態に関与する遺伝子
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
WO2006099543A2 (en) 2005-03-15 2006-09-21 The Regents Of The University Of California Methods for assessing antibody-mediated cytotoxicity
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
JP2006265189A (ja) 2005-03-24 2006-10-05 Kyoto Univ βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法
ES2318918B1 (es) 2005-04-01 2010-02-16 Biotherapix Molecular Medicines, S.L.U. Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones.
WO2006110748A2 (en) 2005-04-08 2006-10-19 The University Of Maryland, Baltimore Response gene to complement 32 (rgc-32) in disease
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
KR20070122497A (ko) 2005-04-22 2007-12-31 제넨테크, 인크. Ｃｄ20 항체로 치매 또는 알츠하이머병을 치료하는 방법
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
WO2006119449A2 (en) 2005-05-04 2006-11-09 Vectorlogics, Inc. Modified adenovirus containing a stabilized antibody
BRPI0610093A2 (pt) 2005-05-05 2008-12-09 Merck & Co Inc composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
EP1888783B1 (en) 2005-05-27 2011-10-26 EVOTEC Neurosciences GmbH Kcnn3 as diagnostic and therapeutic target for alzheimer's disease
US20060272038A1 (en) 2005-05-27 2006-11-30 Michael De Vivo Transgenic Alzheimer's mouse model vectors and uses thereof
MX2007015292A (es) 2005-06-06 2008-02-21 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos.
EA015148B1 (ru) 2005-06-17 2011-06-30 Элан Фарма Интернэшнл Лимитед СПОСОБЫ ОЧИСТКИ Aβ-СВЯЗЫВАЮЩЕГО БЕЛКА, СОДЕРЖАЩЕГО ОБЛАСТЬ FC
US7741448B2 (en) 2005-06-21 2010-06-22 Medical & Biological Laboratories Co., Ltd. Antibody having inhibitory effect on amyloid fibril formation
TW200726482A (en) 2005-06-30 2007-07-16 Merck & Co Inc Method for preparing a covalently cross linked oligomer of amyloid beta peptides
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
JP5102205B2 (ja) 2005-07-13 2012-12-19 コイミュン インコーポレイテッド 触媒免疫グロブリン
WO2007011834A2 (en) 2005-07-15 2007-01-25 The Regents Of The University Of California Compounds and method for the diagnosis and treatment of amyloid associated diseases
WO2007021886A2 (en) 2005-08-10 2007-02-22 Oklahoma Medical Research Foundation Truncated memapsin 2 for use for treating alzheimer's disease
BRPI0614366A2 (pt) 2005-08-11 2009-10-06 Arpi Matossian Rogers peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos
AU2006281980A1 (en) 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
US8124076B2 (en) 2005-08-18 2012-02-28 Ramot At Tel Aviv University Ltd. Single chain antibodies against β-amyloid peptide
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2007077103A (ja) 2005-09-16 2007-03-29 Yokohama City Univ アルツハイマー病の予防又は治療剤
US20080274096A1 (en) 2005-10-03 2008-11-06 Astrazeneca Ab Fusion Proteins Having a Modulated Half-Life in Plasma
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
RU2008120027A (ru) 2005-10-21 2009-11-27 Мерк энд Ко., Инк. (US) Анти-addl моноклональное антитело и его применение
AU2006304804B2 (en) 2005-10-21 2011-06-02 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
US20070092508A1 (en) 2005-10-21 2007-04-26 Recombiant Technologies, Llc Detoxification depot for Alzheimer's disease
JP2009513712A (ja) 2005-11-01 2009-04-02 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
US20090181008A1 (en) 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
US20080014596A1 (en) 2005-11-16 2008-01-17 Jasna Jerecic ADDL Binding to Hippocampal Neurons
CA2630964A1 (en) 2005-11-22 2007-05-31 The Trustees Of The University Of Pennsylvania Antibody treatment of alzheimer's and related diseases
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
WO2007064917A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007067512A2 (en) 2005-12-08 2007-06-14 Merck & Co., Inc. Method for identifying modulators of adprh useful for treating alzheimer's disease
AU2006326283B2 (en) 2005-12-12 2012-01-19 Ac Immune S.A. Therapeutic vaccine
RS52004B (en) 2005-12-12 2012-04-30 F. Hoffmann-La Roche Ag ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION
RU2015111675A (ru) 2005-12-12 2015-08-10 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
US7763245B2 (en) 2005-12-15 2010-07-27 Genentech, Inc. Methods and compositions for targeting polyubiquitin
US20080058276A1 (en) * 2006-01-13 2008-03-06 Cornell Research Foundation, Inc. Alzheimer's disease therapeutics based on pin-1 catalyzed conformational changes in phosphorylated amyloid precursor protein
EP1811304A1 (en) 2006-01-18 2007-07-25 Friedrich-Alexander-Universität Erlangen-Nürnberg Large Aß-peptide binding particles (LAPS) in diagnosis and therapy of Alzheimer's dementia
CN1329413C (zh) 2006-01-23 2007-08-01 南京医科大学 一种治疗或预防老年性痴呆的抗体及其表达载体和在制药中的应用
ES2409844T3 (es) 2006-01-30 2013-06-28 Grifols Therapeutics Inc. Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM
GB0601976D0 (en) 2006-02-01 2006-03-15 Merck Sharp & Dohme Proteins
WO2007088712A1 (ja) 2006-02-02 2007-08-09 National University Corporation Nagoya University 神経細胞の細胞死阻害剤及びスクリーニング方法
WO2007092861A2 (en) 2006-02-06 2007-08-16 Elan Pharmaceuticals, Inc. Inhibitors specific of presenilin-1 and their uses
CA2637775A1 (en) 2006-02-09 2007-08-16 Novartis Ag Antibodies against secreted frizzled related protein-4 (sfrp-4 )
WO2007098417A2 (en) 2006-02-21 2007-08-30 Oklahoma Medical Research Foundation Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
KR20080103560A (ko) 2006-02-22 2008-11-27 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신
US20070196367A1 (en) 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
KR20080097188A (ko) 2006-02-24 2008-11-04 키에시 파르마슈티시 엣스. 피. 에이. 항아밀로이드 면역성성분, 그 제조방법 및 용도
US20100196932A1 (en) 2006-03-02 2010-08-05 The Board Of Trustees Of The University Of Illinois Yeast Reporter System
EP2514824A3 (en) 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
WO2007109107A2 (en) 2006-03-17 2007-09-27 The Trustees Of Columbia University In The City Of New York Atf4 as a therapeutic target in alzheimers disease and other neurological disorders
US20070286858A1 (en) 2006-03-21 2007-12-13 Wyeth Methods and Compositions for Antagonism of RAGE
EP2007385A4 (en) 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
CA2541522A1 (en) 2006-03-28 2007-09-28 E. Rick Preddie A double elisa for alzheimer's disease (ad) with applications for therapeutic vaccines to stop the disease
FR2899107B1 (fr) 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
EP2177536B1 (en) 2006-03-30 2014-06-04 Glaxo Group Limited Antibodies against amyloid-beta peptide
KR20090007374A (ko) 2006-03-31 2009-01-16 더 리전트 오브 더 유니버시티 오브 캘리포니아 신경변성 질환과 알츠하이머병을 치료하고 정상 기억을 향상시키기 위한 방법과 조성물
JP4790013B2 (ja) 2006-04-13 2011-10-12 エーディア株式会社 β−アミロイドの血中分解速度測定によるアルツハイマー病の検定に用いられる方法及び診断試薬
JP5164971B2 (ja) 2006-04-21 2013-03-21 ピープルバイオ，アイ エヌ シー 三次元的相互作用を用いてマルチマー形成ポリペプチドのモノマーからマルチマーを分別検出する方法
CN101058608B (zh) 2006-04-21 2011-02-23 杜如昱 人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
US20090220524A1 (en) 2006-04-25 2009-09-03 The University Of Tokyo Therapeutic agents for alzheimer's disease and cancer
WO2007127393A2 (en) 2006-04-27 2007-11-08 The Mclean Hospital Corporation Treatment and screening methods for promoting neurogenesis
GB0608386D0 (en) 2006-04-27 2006-06-07 Senexis Ltd Compounds
CA2650704A1 (en) 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds
JP2007300856A (ja) 2006-05-11 2007-11-22 Hiroshi Mori アミロイドタンパク質模倣物
US20070292895A1 (en) 2006-05-19 2007-12-20 Xiao-Ping Shi Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
WO2008042024A2 (en) * 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
US7479550B2 (en) 2006-06-02 2009-01-20 The Board Of Regents Of The University Of Texas System Amyloid β gene vaccines
JP4933159B2 (ja) 2006-06-02 2012-05-16 国立大学法人金沢大学 アルツハイマー病の診断方法
US7427342B2 (en) 2006-06-02 2008-09-23 General Electric Company Method and apparatus for shifting current distribution in electrodeionization systems
WO2007144198A2 (en) 2006-06-16 2007-12-21 Umc Utrecht Holding B.V. Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
EP2043687A4 (en) 2006-06-29 2010-03-17 Centocor Ortho Biotech Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
CA2655029A1 (en) * 2006-07-06 2008-01-10 Roskamp Research, Llc Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
CN101490840A (zh) 2006-07-13 2009-07-22 派克汉尼芬公司 吸收emi的间隙填充材料
KR101605207B1 (ko) * 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
WO2008008463A2 (en) 2006-07-14 2008-01-17 Trustees Of Columbia University In The City Of New York METHODS AND COMPOSITIONS FOR DETECTING AND QUANTIFYING SAPPβ
EP1882944B1 (en) 2006-07-28 2009-03-18 VISTA VENTURES GmbH Method for the detection of amyloid-beta oligomers in body fluids
US7705475B2 (en) * 2006-08-03 2010-04-27 Stats Chippac Ltd. Integrated circuit package system
JP2009545756A (ja) 2006-08-04 2009-12-24 ロンザ バイオロジックス ピーエルシー タンパク質凝集を予測し凝集阻害物質を設計する方法
US20090123488A1 (en) 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
US8497246B2 (en) 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
WO2008051326A2 (en) 2006-08-21 2008-05-02 President And Fellows Of Harvard College Identification of contactins and l1- cams as ligands for the amyloid precursor protein
WO2008070229A2 (en) 2006-08-28 2008-06-12 Case Western Reserve University Detection of pathogenic aggregates of protein in a sample by homologous elisa
WO2008027526A1 (en) 2006-08-31 2008-03-06 Biogen Idec Ma Inc. Methods relating to peripheral administration of nogo receptor polypeptides
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
EP2074222A4 (en) 2006-09-06 2010-03-03 Univ Texas METHODS AND COMPOSITIONS FOR DETECTION OF PROTEIN FOLDING DISORDERS
EP2066692B1 (en) 2006-09-08 2012-01-11 VIB, vzw Means and methods for the production of amyloid oligomers
WO2008030251A1 (en) 2006-09-08 2008-03-13 Georgetown University Deglycosylated anti-amyloid beta antibodies
ES2307396B1 (es) 2006-09-14 2009-09-30 Fundacion Para Investigaciones Neurologicas (Fin) Sistemas de eliminacion de sustancias neurotoxicas causantes de enfermedades neurodegenerativas mediante su atrapamiento selectivo por inmunoafinidad en el liquido cefalo-raquideo circulante.
US7375190B2 (en) 2006-09-19 2008-05-20 National Yang-Ming University Recombinant protein and method of screening for agents that modulate polypeptide aggregation
KR20150002879A (ko) 2006-10-02 2015-01-07 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US20100104577A1 (en) 2006-10-10 2010-04-29 Golde Todd E Methods and materials related to anti-a (beta) antibodies
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
JP5153114B2 (ja) 2006-10-12 2013-02-27 知宏 千葉 新規のアルツハイマー病検出方法
US20080113444A1 (en) 2006-10-17 2008-05-15 Pray Todd R Method for detecting oligermization of soluble amyloid beta oligomers
GB0620735D0 (en) 2006-10-18 2006-11-29 Ares Trading Sa Proteins
KR100883132B1 (ko) 2006-10-24 2009-02-10 재단법인서울대학교산학협력재단 아밀로이드 형성 펩타이드 또는 단백질의 가용성 회합체에선택적으로 작용하는 절단제
BRPI0717335A2 (pt) 2006-10-27 2013-12-10 Abbott Biotech Ltd Anticorpos anti-htnfalfa cristalinos
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2083621A4 (en) 2006-11-20 2010-03-24 Satori Pharmaceuticals Inc MODULATORS OF AMYLOID BETA PRODUCTION
EP2102165A2 (en) 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008143708A2 (en) 2006-12-07 2008-11-27 Mayo Foundation For Medical Education And Research Methods and materials related to anti-amyloid antibodies
MX2009006199A (es) 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
WO2008076262A2 (en) 2006-12-15 2008-06-26 Merck & Co., Inc. Receptor for amyloid beta and uses thereof
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
KR100806914B1 (ko) 2007-02-14 2008-02-22 경북대학교 산학협력단 퇴행성 신경질환의 예방 및 치료를 위한 리포칼린 2의 신규한 용도
EP2125015A1 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
GB0704394D0 (en) 2007-03-07 2007-04-11 Senexis Ltd Compounds
US20090022728A1 (en) 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases
EP1978035A1 (en) 2007-04-05 2008-10-08 Hans-Knöll-Institut Leibniz-Institut für Naturstoff-Forschung Anti-amyloid antibodies and their use in diagnosis and therapy of amyloid diseases
PL2148667T3 (pl) 2007-04-12 2013-11-29 Waratah Pharmaceuticals Inc Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
RU2523894C2 (ru) 2007-04-18 2014-07-27 Янссен Альцгеймер Иммунотерапи Предупреждение и лечение церебральной амилоидной ангиопатии
WO2008129023A2 (en) 2007-04-19 2008-10-30 Vib Vzw Oligonucleotide compositions for the treatment of alzheimer's disease
CA2719878C (en) 2007-04-26 2017-08-29 Yale University Prion protein as a receptor for amyloid-beta oligomers
US20100178658A1 (en) 2007-05-30 2010-07-15 The Regents Of The University Of Michigan Screening assays for inhibitors of beta amyloid peptide ion channel formation
PE20090329A1 (es) 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
US20090232801A1 (en) 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
CN101820911B (zh) 2007-06-12 2015-05-06 Ac免疫有限公司 β淀粉样蛋白的人源化抗体
BRPI0812484A2 (pt) 2007-06-12 2018-06-05 Ac Immune Sa anticorpo monoclonal, regiões variáveis de cadeia leve e de cadeia pesada, cdr isolada, polinucleotídeo, composição terapêutica, métodos para tratar doenças e distúrbios, para produzir um anticorpo, para tratar ou aliviar os efeitos de doenças e distúrbios, para reduzir a carga de placas no cérebro de um indivíduo, para reduzir a quantidade de placas no cérebro de um indivíduo, para diminuir a quantidade total de abeta solúvel no cérebro de um indivíduo, para reter ou aumentar a capacidade de memória cognitiva em um indivíduo, de diagnose de ou para diagnosticar uma predisposição para uma doença associada com amilóide ou condição em um paciente, para determinar a extensão de carga de placa amiloidogênica em um tecido de um indivíduo, para monitorar doença residual mínima em um indivíduo e para prever responsividade de um indivíduo, linhagem de células, kit de teste, epítopo abeta
EP2009445A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of a camelid single-domain antibody for detecting an oligomeric form of an amyloid beta peptide and its applications
CN101084909A (zh) 2007-07-03 2007-12-12 福建医科大学附属协和医院 人参皂苷Rg1的新用途
WO2009009768A2 (en) 2007-07-12 2009-01-15 Acumen Pharmaceuticals, Inc. METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
WO2009008891A1 (en) 2007-07-12 2009-01-15 Acumen Pharmaceuticals, Inc. Methods of enhancing cognitive function using non-peptidic compounds
MX2010000368A (es) 2007-07-12 2010-07-02 Acumen Pharmaceuticals Inc Metodos para modificar los oligomeros beta-amiloides usando compuestos no peptidicos.
NZ585110A (en) 2007-10-05 2012-09-28 Genentech Inc Method and compositions for diagnosis and treatment of amyloidosis
EP2238166B1 (en) 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
RU2542967C2 (ru) 2007-10-05 2015-02-27 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
GB0719559D0 (en) 2007-10-05 2007-11-14 Senexis Ltd Compounds
CN101152576A (zh) 2007-10-15 2008-04-02 王延江 防治阿尔茨海默病的药物
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20100173828A1 (en) 2008-07-25 2010-07-08 Abbott Gmbh & Co. Kg Aß(X - 38 .. 43) oligomers, and processes, compositions, and uses thereof
CN102203124A (zh) 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
EP2401300B1 (en) * 2009-02-25 2018-01-10 Academia Sinica ANTI-C[epsilon]mX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies

Also Published As

Publication number Publication date
US10538581B2 (en) 2020-01-21
ECSP088462A (es) 2008-06-30
JP2009517057A (ja) 2009-04-30
US20170022269A1 (en) 2017-01-26
RU2442793C2 (ru) 2012-02-20
ES2527661T3 (es) 2015-01-28
IL209350A0 (en) 2011-01-31
NO20082890L (no) 2008-09-01
PL2289909T3 (pl) 2015-04-30
WO2007062852A3 (en) 2007-07-26
AU2006319358B2 (en) 2012-01-19
IL191588A0 (en) 2008-12-29
ES2524984T3 (es) 2014-12-16
CA2628703C (en) 2019-10-29
JP2016183160A (ja) 2016-10-20
JP2014040453A (ja) 2014-03-06
EP1954718B1 (en) 2014-09-03
GT200800082A (es) 2009-05-22
CN101432302A (zh) 2009-05-13
PL1954718T3 (pl) 2015-04-30
RU2008126242A (ru) 2010-01-10
CA2628703A1 (en) 2007-06-07
PT2289909E (pt) 2015-02-10
EP2289909A1 (en) 2011-03-02
EP1954718A2 (en) 2008-08-13
US9540432B2 (en) 2017-01-10
US20090191190A1 (en) 2009-07-30
ZA200804346B (en) 2009-04-29
CN117903302A (zh) 2024-04-19
US8691224B2 (en) 2014-04-08
JP5475994B2 (ja) 2014-04-16
PT1954718E (pt) 2014-12-16
KR20080090408A (ko) 2008-10-08
BRPI0619249A2 (pt) 2011-09-20
WO2007062852A2 (en) 2007-06-07
US20140127191A1 (en) 2014-05-08
AU2006319358A1 (en) 2007-06-07
CR9969A (es) 2009-08-24
EP2289909B1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
DK1954718T3 (da) Anti-A-globulomer-antistoffer, antigenbindingsgrupper deraf, tilsvarende hybridomer, nucleinsyrer, vektorer, værtsceller, fremgangsmåder til fremstilling af nævnte antistoffer,
US9951125B2 (en) Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
KR101434935B1 (ko) 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
DK2289909T3 (da) Screeningsfremgangsmåde, fremgangsmåde til oprensning af ikke-diffunderende a-beta oligomerer, selektive antistoffer mod nævnte ikke-diffunderingsdygtige a-beta oligomerer og en fremgangsmåde til fremstilling af nævnte antistoffer
AU2012201856A1 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
MX2008007006A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos